Chiesi Farmaceutici SpA has divulged TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Chiesi Farmaceutici SpA has disclosed imidazole derivatives acting as TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Chiesi Farmaceutici SpA has described amido cyclopropyl derivatives acting as lysophospholipid LPA1 receptor (LPAR1; EDG2) antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
A Chiesi Farmaceutici SpA patent details cyclohexane acid derivatives acting as lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists and thus reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Chiesi Farmaceutici SpA has synthesized pyrrolidine derivatives acting as discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis and idiopathic pulmonary fibrosis (IPF).
Chiesi Farmaceutici SpA has synthesized pyridazinyl amino derivatives acting as TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported for be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Chiesi Farmaceutici SpA has agreed to pay Affibody AB up to $214 million in a collaboration and licensing agreement to develop an inhaled treatment for respiratory diseases, with a further $423 million also in the cards if the deal is extended to two more programs. The fees consist of up front and milestone payments, based on certain development, regulatory and commercial achievements, with additional mid-single to low double-digit royalties on sales.
